Aspen Pharmacare Forecasts Over $124M in African Mounjaro Sales

Key Facts

1Aspen Pharmacare expects African sales of Eli Lilly's Mounjaro to exceed 2 billion rand ($124 million) in its current financial year.

2The company plans to launch the drug in Nigeria and Kenya to bolster growth driven by surging demand in South Africa.

Amid the global surge in demand for weight-loss treatments, Aspen Pharmacare has announced ambitious growth targets for its African operations. The company expects sales of Eli Lilly's Mounjaro to exceed 2 billion rand ($124 million) in its current financial year. This forecast is primarily driven by the surging demand observed in South Africa, which has served as a primary launchpad for the drug's regional performance.

The company's expansion strategy involves launching the drug in the Nigerian and Kenyan markets to further bolster its revenue streams. According to market data, Eli Lilly (LLY) shares stood at $1160.08 at the close of September 2, 2026. The partnership highlights the growing importance of emerging market distribution channels for blockbuster pharmaceutical products developed by global leaders like Eli Lilly.

Investors are now watching for the operational execution of these launches in East and West Africa as catalysts for the current financial year. With LLY priced at $1160.08 as of the latest close, the market remains focused on whether the distribution infrastructure in Nigeria and Kenya can replicate the rapid adoption seen in South Africa to meet the $124 million revenue target.